BrainsWay Ltd. BWAY
9.28 USD +0.17 (+1.85%)
As ofNov 18, 2026, 9:55 AM EST
9.14 Day range 9.34
7.14 52-week range 17.40
- YTD
- -2.43%
- 1 year
- +25.55%
News
fool.com BrainsWay: 3 Key Takeaways for Long-Term Investors BrainsWay shipped 130 Deep TMS systems in the third quarter. U.S. insurance reimbursement for SWIFT reached 70 million covered lives.
benzinga.com BrainsWay Q3 2026 Earnings Call Transcript BrainsWay (NASDAQ:BWAY) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com BrainsWay Raises FY2026 Sales Guidance from $68.000M-$70.000M to $70.000M vs $69.283M Est BrainsWay (NASDAQ:BWAY) raises FY2026 sales outlook from $68.000 million-$70.000 million to $70.000 million vs $69.283 million estimate.
benzinga.com BrainsWay Q3 EPS $0.05 Misses $0.09 Estimate, Sales $18.146M Beat $17.891M Estimate BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.09 by 44.44 percent. This is a 150 percent increase over earnings of $0.02 per…
benzinga.com BrainsWay Partners With Mindful Health Solutions To Pursue Strategic Initiatives To Expand Patient Access To Health Treatments BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced a strategic
benzinga.com HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $19 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $19 price target.
benzinga.com BrainsWay, Inland Psychiatric Collaborate On Multi-System Deep TMS Deployment And Mental Health Research Initiatives BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic
